ArticleBioinformation2025
Bioactive glass putty with and without platelet-rich fibrin for periodontal intrabony defects: A prospective comparative study.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontal treatment aims to halt the advancement of tissue destruction on one hand and promote the regeneration of lost periodontal structures on the other hand. Bioactive glass, an alloplastic bone graft material, supports bone regeneration by enhancing the formation of mineralized extracellular matrix through its adsorptive properties and by providing proteins that aid osteoblast function. Platelet-rich fibrin (PRF), a self - derived concentrate having growth factors and leukocytes, can significantly influence the cellular processes involved in periodontal regeneration. The fusion of bioactive glass and PRF may offer an effective approach for treating intrabony defects. In a split-mouth study design, 32 intraosseous defects were treated with either Novabone putty (Control site) or a combination of Novabone putty and PRF (Test site). Documentation of clinical variables was done at baseline, 3, 6, and 9 months after surgery and radiographic bone levels were also evaluated at the postsurgical visits. A significant decrease in PPD and an increase in CAL, relative to baseline measurements were observed in both groups. Attachment level showed modest enhancements in test groups. After 9 months, the test group exhibited a greater amount of bone fill compared to the control group. Thus, autologous PRF combined with bioactive glass bone graft (Novabone putty) has proven to be effective in enhancing both clinical and radiographic results for periodontal intrabony defects and offers additional advantages when compared to bone grafts by them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.